Investor Presentaiton

Recent Late-Phase R&D Highlights • • Clazakizumab for reduction of cardiovascular events in patients with End-Stage Kidney Disease (ESKD) Well-characterized link of inflammation and cardiovascular morbidity and mortality in patients with ESKD • • Positive phase 2b data; Phase 3 prepared to start 2Q 2024 Garadacimab for Hereditary Angioedema . • High efficacy, Favorable safety and tolerability; patient-friendly presentation and regimen Global submissions and regulatory review underway; First approval expected 4Q 2024 HIZENTRAⓇ for Dermatomyositis 13 • 5-year mortality rate 10-30%, high comorbidity; Better treatments needed Enrolment complete for phase 3; Data expected 3Q 2024 Adjuvanted, cell-based Quadrivalent Influenza Vaccine (aQIVC) • • aQIVc combines benefits of MF59Ⓡ adjuvant, higher antigen dose and cell-derived antigen to increased influenza protection via heightened immune response Phase III Immunogenicity study (50 years+) enrolment completed ahead of schedule; Data expected 4Q 2024 Driven by Our Promise CSL

View entire presentation